{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T17:00:14Z","timestamp":1791910814369,"version":"4.3.4"},"reference-count":46,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,7]],"date-time":"2023-09-07T00:00:00Z","timestamp":1694044800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100001316","name":"Abbott Laboratories","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001316","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100003085","name":"Longer Life Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100003085","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["UL1TR002345"],"award-info":[{"award-number":["UL1TR002345"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009340","name":"Children's Discovery Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009340","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.esmoop.2023.101830","type":"journal-article","created":{"date-parts":[[2023,11,17]],"date-time":"2023-11-17T00:37:57Z","timestamp":1700181477000},"page":"101830","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"title":["Risk profiles and incidence of cardiovascular events across different cancer types"],"prefix":"10.1016","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7371-5742","authenticated-orcid":false,"given":"J.D.","family":"Mitchell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Laurie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Q.","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Dreyfus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Lane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9458-0154","authenticated-orcid":false,"given":"D.J.","family":"Lenihan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.esmoop.2023.101830_bib1","series-title":"Global action plan for the prevention and control of noncommunicable diseases 2013-2020","year":"2013"},{"key":"10.1016\/j.esmoop.2023.101830_bib2","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1097\/00001648-199803000-00013","article-title":"Cancer risk of patients discharged with acute myocardial infarct","volume":"9","author":"Dreyer","year":"1998","journal-title":"Epidemiology"},{"key":"10.1016\/j.esmoop.2023.101830_bib3","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.ejca.2011.09.015","article-title":"Risk of coronary heart disease in patients with cancer: a nationwide follow-up study from Sweden","volume":"418","author":"Z\u00f6ller","year":"2012","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.esmoop.2023.101830_bib4","doi-asserted-by":"crossref","first-page":"106","DOI":"10.15420\/cfr.2019.1.2","article-title":"Bidirectional relationship between cancer and heart failure: old and new issues in cardio-oncology","volume":"5","author":"Bertero","year":"2019","journal-title":"Card Fail Rev"},{"key":"10.1016\/j.esmoop.2023.101830_bib5","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2021.729713","article-title":"Cancer-a major cardiac comorbidity with implications on cardiovascular metabolism","volume":"12","author":"Finke","year":"2021","journal-title":"Front Physiol"},{"issue":"12","key":"10.1016\/j.esmoop.2023.101830_bib6","doi-asserted-by":"crossref","first-page":"3737","DOI":"10.3390\/cancers12123737","article-title":"Cardiovascular health during and after cancer therapy","volume":"12","author":"Ruddy","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"20","key":"10.1016\/j.esmoop.2023.101830_bib7","doi-asserted-by":"crossref","first-page":"2536","DOI":"10.1016\/j.jacc.2017.09.1096","article-title":"Cardiovascular complications of cancer therapy: best practices in diagnosis, prevention, and management: part 1","volume":"70","author":"Chang","year":"2017","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"20","key":"10.1016\/j.esmoop.2023.101830_bib8","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.1016\/j.jacc.2017.09.1095","article-title":"Cardiovascular complications of cancer therapy: best practices in diagnosis, prevention, and management: part 2","volume":"70","author":"Chang","year":"2017","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.esmoop.2023.101830_bib9","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/s11886-017-0846-x","article-title":"Cardiac complications of cancer therapy: pathophysiology, identification, prevention, treatment, and future directions","volume":"19","author":"Jain","year":"2017","journal-title":"Curr Cardiol Rep"},{"key":"10.1016\/j.esmoop.2023.101830_bib10","doi-asserted-by":"crossref","first-page":"e445","DOI":"10.1016\/S1470-2045(17)30535-1","article-title":"Cardiotoxic effects of anthracycline-based therapy: what is the evidence and what are the potential harms?","volume":"18","author":"Levis","year":"2017","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.esmoop.2023.101830_bib11","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1093\/eurheartj\/ehab674","article-title":"Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement","volume":"43","author":"Herrmann","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.esmoop.2023.101830_bib12","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/s11883-018-0702-5","article-title":"Chemotherapeutic agents and the risk of ischemia and arterial thrombosis","volume":"20","author":"Hassan","year":"2018","journal-title":"Curr Atheroscler Rep"},{"key":"10.1016\/j.esmoop.2023.101830_bib13","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.ijrobp.2009.09.064","article-title":"Radiation-related heart disease: current knowledge and future prospects","volume":"76","author":"Darby","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"10.1016\/j.esmoop.2023.101830_bib14","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.jaccao.2021.06.003","article-title":"Cardiovascular manifestations from therapeutic radiation: a multidisciplinary expert consensus statement from the International Cardio-Oncology Society","volume":"3","author":"Mitchell","year":"2021","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.esmoop.2023.101830_bib15","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1016\/S1470-2045(18)30608-9","article-title":"Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study","volume":"19","author":"Salem","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.esmoop.2023.101830_bib16","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.yjmcc.2021.07.006","article-title":"Immune checkpoint inhibitor cardiotoxicity: breaking barriers in the cardiovascular immune landscape","volume":"160","author":"Zhu","year":"2021","journal-title":"J\u00a0Mol Cell Cardiol"},{"issue":"7","key":"10.1016\/j.esmoop.2023.101830_bib17","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s11912-021-01070-6","article-title":"Cardiotoxicity of immune checkpoint inhibitors","volume":"23","author":"Patel","year":"2021","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/j.esmoop.2023.101830_bib18","doi-asserted-by":"crossref","DOI":"10.4061\/2011\/394740","article-title":"Arterial and venous thrombosis in cancer patients","volume":"2011","author":"Blann","year":"2011","journal-title":"Cardiol Res Pract"},{"key":"10.1016\/j.esmoop.2023.101830_bib19","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1016\/j.clinthera.2009.11.020","article-title":"Anemia and thrombocytopenia in patients undergoing chemotherapy for solid tumors: a descriptive study of a large outpatient oncology practice database, 2000-2007","volume":"31","author":"Wu","year":"2009","journal-title":"Clin Ther"},{"issue":"7","key":"10.1016\/j.esmoop.2023.101830_bib21","first-page":"900","article-title":"Shared risk factors for cardiovascular disease and cancer: implications for preventive health and clinical care in oncology patients","volume":"32","author":"Johnson","year":"2016","journal-title":"Can J Cardiol"},{"issue":"2","key":"10.1016\/j.esmoop.2023.101830_bib22","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1161\/CIRCULATIONAHA.119.042276","article-title":"Cardio-immuno-oncology","volume":"141","author":"Zaha","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.esmoop.2023.101830_bib23","doi-asserted-by":"crossref","first-page":"3889","DOI":"10.1093\/eurheartj\/ehz766","article-title":"A\u00a0population-based study of cardiovascular disease mortality risk in US cancer patients","volume":"40","author":"Sturgeon","year":"2019","journal-title":"Eur Heart J"},{"key":"10.1016\/j.esmoop.2023.101830_bib24","doi-asserted-by":"crossref","first-page":"3898","DOI":"10.1093\/eurheartj\/ehz781","article-title":"From trends to transformation: where cardio-oncology is to make a difference","volume":"40","author":"Herrmann","year":"2019","journal-title":"Eur Heart J"},{"issue":"18","key":"10.1016\/j.esmoop.2023.101830_bib25","article-title":"Cardiovascular toxicity related to cancer treatment: a pragmatic approach to the American and European Cardio-oncology Guidelines","volume":"9","author":"Alexandre","year":"2020","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.esmoop.2023.101830_bib26","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/S0140-6736(19)31674-5","article-title":"Medium and long-term risks of specific cardiovascular diseases in survivors of 20 adult cancers: a population-based cohort study using multiple linked UK electronic health records databases","volume":"394","author":"Strongman","year":"2019","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.esmoop.2023.101830_bib27","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1200\/JCO.2015.64.0409","article-title":"Cardiovascular disease among survivors of adult-onset cancer: a community-based retrospective cohort study","volume":"34","author":"Armenian","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2023.101830_bib28","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.jaccao.2022.01.100","article-title":"Incident cardiovascular disease among adults with cancer: a population-based cohort study","volume":"4","author":"Paterson","year":"2022","journal-title":"JACC CardioOncol"},{"issue":"1","key":"10.1016\/j.esmoop.2023.101830_bib29","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.jaccao.2022.01.102","article-title":"Does cardiovascular mortality overtake cancer mortality during cancer survivorship? An English retrospective cohort study","volume":"4","author":"Strongman","year":"2022","journal-title":"JACC CardioOncol"},{"issue":"1","key":"10.1016\/j.esmoop.2023.101830_bib30","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1097\/00005650-199801000-00004","article-title":"Comorbidity measures for use with administrative data","volume":"36","author":"Elixhauser","year":"1998","journal-title":"Med Care"},{"key":"10.1016\/j.esmoop.2023.101830_bib31","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1161\/01.STR.0000032240.28636.BD","article-title":"Validating administrative data in stroke research","volume":"33","author":"Tirschwell","year":"2002","journal-title":"Stroke"},{"key":"10.1016\/j.esmoop.2023.101830_bib32","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ahj.2004.02.013","article-title":"Accuracy of Medicare claims-based diagnosis of acute myocardial infarction: estimating positive predictive value on the basis of review of hospital records","volume":"148","author":"Kiyota","year":"2004","journal-title":"Am Heart J"},{"key":"10.1016\/j.esmoop.2023.101830_bib33","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1002\/pds.1518","article-title":"Validation of ICD-9 codes with a high positive predictive value for incident strokes resulting in hospitalization using Medicaid health data","volume":"17","author":"Roumie","year":"2008","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.esmoop.2023.101830_bib34","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1161\/01.STR.0000174293.17959.a1","article-title":"Coding of stroke and stroke risk factors using international classification of diseases, revisions 9 and 10","volume":"36","author":"Kokotailo","year":"2005","journal-title":"Stroke"},{"issue":"suppl 1","key":"10.1016\/j.esmoop.2023.101830_bib35","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1002\/pds.2313","article-title":"A\u00a0systematic review of validated methods for identifying heart failure using administrative data","volume":"21","author":"Saczynski","year":"2012","journal-title":"Pharmacoepidemiology Drug Saf"},{"issue":"11","key":"10.1016\/j.esmoop.2023.101830_bib36","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1002\/ejhf.1920","volume":"22","author":"Lyon","year":"2020","journal-title":"Eur J Heart Fail"},{"issue":"1","key":"10.1016\/j.esmoop.2023.101830_bib37","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.115.002661","article-title":"Cancer therapy-related cardiac dysfunction and heart failure part 1: definitions, pathophysiology, risk factors, and imaging","volume":"9","author":"Bloom","year":"2016","journal-title":"Circ Heart Fail"},{"issue":"33","key":"10.1016\/j.esmoop.2023.101830_bib38","doi-asserted-by":"crossref","first-page":"4008","DOI":"10.1200\/JCO.2016.68.3482","article-title":"Statins are associated with reduced mortality in multiple myeloma","volume":"34","author":"Sanfilippo","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"16","key":"10.1016\/j.esmoop.2023.101830_bib39","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1161\/CIRCULATIONAHA.121.056810","article-title":"Cardiovascular safety of degarelix versus leuprolide in patients with prostate cancer: the primary results of the PRONOUNCE randomized trial","volume":"144","author":"Lopes","year":"2021","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.esmoop.2023.101830_bib40","doi-asserted-by":"crossref","first-page":"e55","DOI":"10.1161\/ATVBAHA.119.313046","article-title":"Cardiovascular effects of androgen deprivation therapy in prostate cancer: contemporary meta-analyses","volume":"40","author":"Hu","year":"2020","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"10","key":"10.1016\/j.esmoop.2023.101830_bib41","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1016\/j.annonc.2020.07.010","article-title":"Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensus","volume":"31","author":"Curigliano","year":"2020","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.esmoop.2023.101830_bib42","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s10549-014-3253-7","article-title":"Trastuzumab interruption and treatment-induced cardiotoxicity in early HER2-positive breast cancer","volume":"149","author":"Yu","year":"2015","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.esmoop.2023.101830_bib43","doi-asserted-by":"crossref","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","article-title":"2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.esmoop.2023.101830_bib44","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s11886-022-01834-x","article-title":"Recent advances in serum biomarkers for risk stratification and patient management in cardio-oncology","volume":"25","author":"Joolharzadeh","year":"2023","journal-title":"Curr Cardiol Rep"},{"issue":"1","key":"10.1016\/j.esmoop.2023.101830_bib45","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1038\/s41467-020-15639-5","article-title":"Fatal heart disease among cancer patients","volume":"11","author":"Stoltzfus","year":"2020","journal-title":"Nat Commun"},{"issue":"6","key":"10.1016\/j.esmoop.2023.101830_bib46","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1053\/j.seminoncol.2019.11.002","article-title":"Cardio-oncological management of patients","volume":"46","author":"Cardinale","year":"2019","journal-title":"Semin Oncol"},{"issue":"22","key":"10.1016\/j.esmoop.2023.101830_bib47","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1200\/JCO.19.00231","article-title":"Prospective study of cardiac events during proteasome inhibitor therapy for relapsed multiple myeloma","volume":"37","author":"Cornell","year":"2019","journal-title":"J\u00a0Clin Oncol"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702923010657?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702923010657?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T20:33:38Z","timestamp":1761856418000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702923010657"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":46,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["S2059702923010657"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2023.101830","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk profiles and incidence of cardiovascular events across different cancer types","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2023.101830","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"101830"}}